Dot1L-H3K79me2-Tbx6 Axis: A Novel Therapeutic Target for Preventing Cardiac Failure
- 1 August 2025
- journal article
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 137 (4) , 513-515
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- DOT1L regulates chamber-specific transcriptional networks during cardiogenesis and mediates postnatal cell cycle withdrawalNature Communications, 2022
- Epigenetic regulation in cardiovascular disease: mechanisms and advances in clinical trialsSignal Transduction and Targeted Therapy, 2022
- Modeling Human TBX5 Haploinsufficiency Predicts Regulatory Networks for Congenital Heart DiseaseDevelopmental Cell, 2020
- Preclinical evidence for the therapeutic value of TBX5 normalization in arrhythmia controlCardiovascular Research, 2020
- The DOT1L inhibitor Pinometostat decreases the host-response against infections: Considerations about its use in human therapyScientific Reports, 2019
- Cardiomyocyte gene programs encoding morphological and functional signatures in cardiac hypertrophy and failureNature Communications, 2018
- DOT1L-mediated H3K79me2 modification critically regulates gene expression during cardiomyocyte differentiationCell Death & Differentiation, 2014
- Genome-wide analysis of histone marks identifying an epigenetic signature of promoters and enhancers underlying cardiac hypertrophyProceedings of the National Academy of Sciences, 2013
- Principles and challenges of genome-wide DNA methylation analysisNature Reviews Genetics, 2010
- Chromatin Modifications and Their FunctionCell, 2007